Clarametyx Biosciences

Pneumagen

This clinical-stage biotech company develops intranasal antiviral drugs to prevent and treat respiratory tract infections for patients with chronic lung diseases.

Calluna Pharma

This clinical-stage company develops monoclonal antibodies to treat inflammatory and fibrotic diseases for patients with conditions like idiopathic pulmonary fibrosis and chronic kidney disease.

Phaxiam

The company develops bacteriophage-based treatments to combat antibiotic-resistant bacterial infections for patients with severe hospital-acquired or chronic respiratory conditions.

Aqualung

Aqualung Therapeutics develops immunotherapeutic monoclonal antibodies for patients suffering from inflammatory lung injuries and life-threatening fibrosis.

Breath Therapeutics

This biopharmaceutical company develops inhaled drug-aerosol therapies for patients with bronchiolitis obliterans syndrome and other severe respiratory diseases.

Enterprise Therapeutics

This biopharmaceutical company develops novel muco-regulatory therapies for patients with respiratory diseases including cystic fibrosis, asthma and chronic obstructive pulmonary disease.

Altesa BioSciences

This company develops antiviral medicines for patients with chronic lung diseases such as COPD and asthma to prevent respiratory infections and illness flare-ups.

Kither Biotech

This company develops inhaled therapies for patients with respiratory diseases such as chronic obstructive pulmonary disease and cystic fibrosis.